Immunoqure Ag

Fit Biotech Oyj Plc

Fit Biotech Oy

Valipharma

Helsingin Yliopiston Rahastot

Annamari Ranki

Kai Krohn

Annalisa Macagno

Adrian Hayday

Kai Kisand

Part Peterson

Edward Stuart

Shimobi Onuoha

Andres Männik

Mart Ustav

Ene Ustav

Urve Toots

Vesna Blazevic

Marja Tähtinen

Leena Karenko

Riitta Lahesmaa

Sonja Hahtola

Soile Tuomela

Päivi Peltomäki

Kai J E Krohn

Marketta Kähkönen

Ritva Karhu

Tapio Visakorpi

Boguslaw Nedoszytko

Pärt Peterson

Wael University Of Sharjah Hassan

Emilia Carlsson

Kristian Ovaska

Sampsa Hautaniemi

Markku Helle

Valtteri Häyry

Andres Mannik

Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human Auto-Immunosome and corresponding monoclonal antibody reservoir are provided. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy of are described.

Nucleic acid molecules encoding monoclonal antibodies specific for IL-17F

Nucleic acid molecules encoding monoclonal antibodies specific for IL-22

Provided is a novel method of isolating and producing human antibodies with desired specificity from human B cells. In particular, a method of isolating human antibodies from memory B cells obtained from patients which suffer from a disease which is caused by or involves activation of the immune system, for example autoimmune and inflammatory disorders is described.

Method of isolating human antibodies

A method for treating an HIV disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a DNA vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a DNA sequence encoding a nuclear-anchoring protein, where the nuclear-anchoring protein comprises: (i) a DNA binding domain which binds to a specific DNA binding sequence, and (ii) a functional domain of the Bovine Papilloma Virus Type 1 E2 protein, where the functional domain binds to a nuclear component; (b) a multimerized DNA sequence that forms a binding site for the nuclear anchoring protein; and (c) at least one expression cassette comprising a DNA sequence encoding a protein or peptide that stimulates an immune response specific to the protein or peptide; where the expression vector lacks an origin of replication functional in mammalian cells.

Methods of treating HIV diseases using novel expression vectors

Nucleic acid molecules encoding moonoclonal antibodies speceific for IL17F

The present invention relates to the fields of genetics and oncology and provides methods for detecting cutaneous T-cell lymphomas (CTCL) or susceptibility to CTCL. Specifically, the present invention relates to a novel method for the diagnosis and follow-up of CTCL or CTCL subtype, the method comprising determination of expression of one or more genes, gene fragments or gene products. The present invention further relates to a novel method of detecting the response to CTCL therapy, the method comprising determining expression of one or more genes or gene fragments or gene products in a biological sample. The present invention further relates to a novel method of developing or improving CTCL therapy or developing anti-CTCL medicament, the method comprising screening agents affecting one or several of the genes or gene products. The present invention further relates to a novel method of treating CTCL patients, the method comprising affecting one or several of the genes or gene products. The present invention further relates to a novel test kit, the kit comprising the necessary means for detecting one or more genes, gene fragments or gene products. The present invention also relates to a use of one or more genes, gene fragments or gene products for determination, diagnosis or follow-up of CTCL or CTCL subtype and for detection of the response to CTCL therapy. The present invention also relates to a use of one or more target molecules for CTCL therapy or for the preparation of a medicament for treating CTCL.

Methods and means related to diseases

The present invention relates to novel methods for the diagnosis and therapy of lymphoproliferative diseases. Specifically, the present invention relates to novel methods for the diagnosis and therapy taking advantage of the detection of chromosomal breakpoints in chromosome 12 and/or translocation of chromosomal material from chromosome 12, said chromosomal breakpoints and/or translocation(s) being associated with lymphoproliferative diseases, such as primary cutaneous T-cell lymphomas (CTCL). The present invention further relates to the use of neuron navigator 3 gene (NAV3) or an equivalent or functional fragment thereof involved in chromosomal breakpoints in chromosome 12 and/or translocations thereof, said gene and/or translocations thereof being associated with lymphoproliferative diseases, such as primary cutaneous T-cell lymphomas (CTCL), as a diagnostic and therapeutic agent. The present invention also relates to the development of therapy.

Method for the diagnosis of lymphoproliferative diseases

The present invention relates to novel vectors, to DNA vaccines and gene therapeutics containing the vectors, to methods for the preparation of the vectors and DNA vaccines and gene therapeutics containing the vectors, and to therapeutic uses of the vectors. The novel vectors comprise (a) an expression cassette of a gene of a nuclear-anchoring protein, which contains (i) a DNA binding domain capable of binding to a specific DNA sequence and (ii) a functional domain capable of binding to a nuclear component and (b) a multimerized DNA sequence forming a binding site for the anchoring protein, and optionally (c) one or more expression cassettes of a DNA sequence of interest. The vectors lack a papilloma virus origin of replication.

Expression vectors and uses thereof

The present invention relates to novel vectors, to DNA vaccines and gene therapeutics containing said vectors, to methods for the preparation of the vectors and DNA vaccines and gene therapeutics, and to therapeutic uses of said vectors. More specifically, the present invention relates to novel vectors comprising an expression cassette of a gene of a nuclear-anchoring protein, which contains a DNA binding domain capable of binding to a specific DNA sequence and a functional domain capable of binding to a nuclear component and a multimerized DNA sequence forming a binding site for the nuclear-anchoring protein, and optionally an expression cassette of a gene, genes or a DNA sequence or DNA sequences of interest. The present invention further relates to DNA vaccines and gene therapeutics containing the novel vectors, to methods for the preparation of the novel vectors and the DNA vaccines and gene therapeutics.

Growing community of inventors

Helsinki, Finland

Annamari Ranki